High-density lipoproteins: A consensus statement from the National Lipid Association

Journal of Clinical Lipidology

Volumn 7, Issue 5, 2013, Pages 484-525

  Toth, Peter P ^a,b,c   Barter, Philip J ^d   Rosenson, Robert S ^e   Boden, William E ^f   Chapman, M John ^g   Cuchel, Marina ^h   D'Agostino Sr , Ralph B ⁱ   Davidson, Michael H ^j   Davidson, W Sean ^k   Heinecke, Jay W ^l   Karas, Richard H ^m   Kontush, Anatol ^g   Krauss, Ronald M ⁿ   Miller, Michael ^o   Rader, Daniel J ^h  

^a CGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d HEART RESEARCH INSTITUTE   (Australia)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f ALBANY MEDICAL COLLEGE   (United States)

^g INSERM   (France)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ BOSTON UNIVERSITY   (United States)

^j UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^k UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^l UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^m TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^o UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Association Low density lipoprotein cholesterol; Cardiovascular disease CVD; HDL hypothesis National Lipid; HDL C; High density lipoprotein cholesterol; Non HDL C

Indexed keywords

ANACETRAPIB; APOLIPOPROTEIN; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; EVACETRAPIB; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TORCETRAPIB;

ARTICLE; BEDTIME DOSAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DENATURING GRADIENT GEL ELECTROPHORESIS; DENSITY GRADIENT; DISEASE MARKER; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INTERVENTION STUDY; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; THERAPY EFFECT; TWO DIMENSIONAL GEL ELECTROPHORESIS; ULTRACENTRIFUGATION;

CARDIOVASCULAR DISEASE; CVD; HDL HYPOTHESIS; HDL-C; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL; LOW-DENSITY LIPOPROTEIN CHOLESTEROL; NATIONAL LIPID ASSOCIATION; NON-HDL-C;

ANIMALS; CARDIOVASCULAR DISEASES; CONSENSUS; HUMANS; LIPOPROTEINS, HDL; MOLECULAR TARGETED THERAPY; RISK FACTORS; SOCIETIES, SCIENTIFIC;

EID: 84884995326     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2013.08.001     Document Type: Article

References (268)

1. Emerging Risk Factors Collaboration E. Di Angelantonio, and N. Sarwar Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
2. K.A. Rye, C.A. Bursill, G. Lambert, F. Tabet, and P.J. Barter The metabolism and anti-atherogenic properties of HDL J Lipid Res 50 suppl 2009 S195 S200
3. T.M. Teslovich, K. Musunuru, and A.V. Smith Biological, clinical and population relevance of 95 loci for blood lipids Nature 466 2010 707 713
4. J.J. Badimon, L. Badimon, and V. Fuster Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit J Clin Invest 85 1990 1234 1241
5. E.M. Rubin, R.M. Krauss, E.A. Spangler, J.G. Verstuyft, and S.M. Clift Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI Nature 353 1991 265 267
6. A.C. Liu, R.M. Lawn, J.G. Verstuyft, and E.M. Rubin Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice J Lipid Res 35 1994 2263 2267
7. A.S. Plump, C.J. Scott, and J.L. Breslow Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse Proc Natl Acad Sci U S A 91 1994 9607 9611
8. S.E. Nissen, T. Tsunoda, and E.M. Tuzcu Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2003 2292 2300
9. J.C. Tardif, J. Gregoire, and P.L. L'Allier Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial JAMA 297 2007 1675 1682
10. W.E. Boden, J.L. Probstfield, and T. Anderson Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
11. G.G. Schwartz, A.G. Olsson, and M. Abt Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
12. P.J. Barter, M. Caulfield, and M. Eriksson Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
13. J.W. Gofman, W. Young, and R. Tandy Ischemic heart disease, atherosclerosis, and longevity Circulation 34 1966 679 697
14. G.J. Miller, and N.E. Miller Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease Lancet 1 1975 16 19
15. G.G. Rhoads, C.L. Gulbrandsen, and A. Kagan Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men N Engl J Med 294 1976 293 298
16. T. Gordon, W.P. Castelli, M.C. Hjortland, W.B. Kannel, and T.R. Dawber High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study Am J Med 62 1977 707 714
17. G. Assmann, and H. Funke HDL metabolism and atherosclerosis J Cardiovasc Pharmacol 16 suppl 9 1990 S15 S20
18. U. Goldbourt, and J.H. Medalie High density lipoprotein cholesterol and incidence of coronary heart disease-the Israeli Ischemic Heart Disease Study Am J Epidemiol 109 1979 296 308
19. U. Goldbourt, S. Yaari, and J.H. Medalie Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men Arterioscler Thromb Vasc Biol 17 1997 107 113
20. G. Assmann, H. Schulte, A. von Eckardstein, and Y. Huang High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport Atherosclerosis 124 suppl 1996 S11 S20
21. T.A. Pearson, B.H. Bulkley, S.C. Achuff, P.O. Kwiterovich, and L. Gordis The association of low levels of HDL cholesterol and arteriographically defined coronary artery disease Am J Epidemiol 109 1979 285 295
22. T.A. Pearson Coronary arteriography in the study of the epidemiology of coronary artery disease Epidemiol Rev 6 1984 140 166
23. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel Arch Intern Med 148 1988 36 69
24. W.P. Castelli, and K. Anderson A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study Am J Med 80 1986 23 32
25. W.P. Castelli Epidemiology of coronary heart disease: the Framingham study Am J Med 76 1984 4 12
26. R.D. Abbott, P.W. Wilson, W.B. Kannel, and W.P. Castelli High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study Arteriosclerosis 8 1988 207 211
27. M. Miller, L.A. Mead, P.O. Kwiterovich Jr., and T.A. Pearson Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease Am J Cardiol 65 1990 1 5
28. G.S. Ginsburg, C. Safran, and R.C. Pasternak Frequency of low serum high-density lipoprotein cholesterol levels in hospitalized patients with "desirable" total cholesterol levels Am J Cardiol 68 1991 187 192
29. J.J. Genest, J.R. McNamara, D.N. Salem, and E.J. Schaefer Prevalence of risk factors in men with premature coronary artery disease Am J Cardiol 67 1991 1185 1189
30. P.A. Romm, C.E. Green, K. Reagan, and C.E. Rackley Relation of serum lipoprotein cholesterol levels to presence and severity of angiographic coronary artery disease Am J Cardiol 67 1991 479 483
31. M. Miller, A. Seidler, P.O. Kwiterovich, and T.A. Pearson Long-term predictors of subsequent cardiovascular events with coronary artery disease and 'desirable' levels of plasma total cholesterol Circulation 86 1992 1165 1170
32. D.J. Gordon, J. Knoke, J.L. Probstfield, R. Superko, and H.A. Tyroler High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial Circulation 74 1986 1217 1225
33. D.J. Gordon, J.L. Probstfield, and R.J. Garrison High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies Circulation 79 1989 8 15
34. M.H. Frick, O. Elo, and K. Haapa Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med 317 1987 1237 1245
35. H.B. Rubins, S.J. Robins, and D. Collins Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group N Engl J Med 341 1999 410 418
36. S.J. Robins, D. Collins, and J.T. Wittes Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial JAMA 285 2001 1585 1591
37. C.M. Ballantyne, J.A. Herd, and L.L. Ferlic Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy Circulation 99 1999 736 743
38. B.G. Brown, X.Q. Zhao, and M.C. Cheung Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence J Clin Lipidol 1 2007 88 94
39. NIH Consensus conference. Triglyceride, high-density lipoprotein, and coronary heart disease. NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease JAMA 269 1993 505 510
40. W.B. Kannel High-density lipoproteins: epidemiologic profile and risks of coronary artery disease Am J Cardiol 52 1983 9B 12B
41. W.B. Kannel, and P.W. Wilson Comparison of risk profiles for cardiovascular events: implications for prevention F.M. Abboud, Advances in Internal Medicine 1996 Mosby Yearbook Chicago, IL 39 66
42. P.W. Wilson, and W.B. Kannel Hypercholesterolemia and coronary risk in the elderly: The Framingham Study Am J Geriatr Cardiol 2 1993 56
43. M.C. Corti, J.M. Guralnik, and M.E. Salive HDL cholesterol predicts coronary heart disease mortality in older persons JAMA 274 1995 539 544
44. W.B. Kannel, and P.W. Wilson Efficacy of lipid profiles in prediction of coronary disease Am Heart J 124 1992 768 774
45. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
46. L.M. Sullivan, J.M. Massaro, and R.B. D'Agostino Sr. Presentation of multivariate data for clinical use: the Framingham Study risk score functions Stat Med 23 2004 1631 1660
47. R.B. D'Agostino Sr., R.S. Vasan, and M.J. Pencina General cardiovascular risk profile for use in primary care: the Framingham Heart Study Circulation 117 2008 743 753
48. C.T. Sempos, J.I. Cleeman, and M.D. Carroll Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel JAMA 269 1993 3009 3014
49. C.J. Glueck, R.W. Fallat, F. Millett, P. Gartside, R.C. Elston, and R.C. Go Familial hyper-alpha-lipoproteinemia: studies in eighteen kindreds Metabolism 24 1975 1243 1265
50. A. Inazu, M.L. Brown, and C.B. Hesler Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation N Engl J Med 323 1990 1234 1238
51. K. Hirano, S. Yamashita, and N. Nakajima Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity Arterioscler Thromb Vasc Biol 17 1997 1053 1059
52. Y. Arai, N. Hirose, and K. Yamamura Deficiency of cholesteryl ester transfer protein and gene polymorphisms of lipoprotein lipase and hepatic lipase are not associated with longevity J Mol Med (Berl) 81 2003 102 109
53. T.A. Koropatnick, J. Kimbell, and R. Chen A prospective study of high-density lipoprotein cholesterol, cholesteryl ester transfer protein gene variants, and healthy aging in very old Japanese-American men J Gerontol A Biol Sci Med Sci 63 2008 1235 1240
54. J. Rhyne, M.J. Ryan, C. White, T. Chimonas, and M. Miller The two novel CETP mutations Gln87X and Gln165X in a compound heterozygous state are associated with marked hyperalphalipoproteinemia and absence of significant coronary artery disease J Mol Med 84 2006 647 650
55. M. Vergeer, S.J. Korporaal, and R. Franssen Genetic variant of the scavenger receptor BI in humans N Engl J Med 364 2011 136 145
56. B.F. Voight, G.M. Peloso, and M. Orho-Melander Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study Lancet 380 2012 572 580
57. J.W. Heinecke The protein cargo of HDL: implications for vascular wall biology and therapeutics J Clin Lipidol 4 2010 371 375
58. C.M. Ballantyne Clinical Lipidology: A Companion to Braunwald's Heart Disease 2009 Saunders/Elsevier Philadelphia, PA
59. M. Miller, and M. Zhan Factors influencing coronary risk in low HDL syndromes Atherosclerosis 169 2003 347 348
60. J. Johansson, L.A. Carlson, C. Landou, and A. Hamsten High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients Arterioscler Thromb 11 1991 174 182
61. K.K. Berneis, and R.M. Krauss Metabolic origins and clinical significance of LDL heterogeneity J Lipid Res 43 2002 1363 1379
62. R.J. Havel, H.A. Eder, and J.H. Bragdon The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum J Clin Invest 34 1955 1345 1353
63. D.W. Anderson, A.V. Nichols, S.S. Pan, and F.T. Lindgren High density lipoprotein distribution. Resolution and determination of three major components in a normal population sample Atherosclerosis 29 1978 161 179
64. P.T. Williams, and D.E. Feldman Prospective study of coronary heart disease vs. HDL2, HDL3, and other lipoproteins in Gofman's Livermore Cohort Atherosclerosis 214 2011 196 202
65. P.J. Blanche, E.L. Gong, T.M. Forte, and A.V. Nichols Characterization of human high-density lipoproteins by gradient gel electrophoresis Biochim Biophys Acta 665 1981 408 419
66. B.F. Asztalos, L.A. Cupples, and S. Demissie High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study Arterioscler Thromb Vasc Biol 24 2004 2181 2187
67. M.J. Chapman, S. Goldstein, D. Lagrange, and P.M. Laplaud A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum J Lipid Res 22 1981 339 358
68. J.T. Cone, J.P. Segrest, B.H. Chung, J.B. Ragland, S.M. Sabesin, and A. Glasscock Computerized rapid high resolution quantitative analysis of plasma lipoproteins based upon single vertical spin centrifugation J Lipid Res 23 1982 923 935
69. K.R. Kulkarni, S.M. Marcovina, R.M. Krauss, D.W. Garber, A.M. Glasscock, and J.P. Segrest Quantification of HDL2 and HDL3 cholesterol by the Vertical Auto Profile-II (VAP-II) methodology J Lipid Res 38 1997 2353 2364
70. K.R. Kulkarni Cholesterol profile measurement by vertical auto profile method Clin Lab Med 26 2006 787 802
71. B.F. Asztalos, C.H. Sloop, L. Wong, and P.S. Roheim Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations Biochim Biophys Acta 1169 1993 291 300
72. B.F. Asztalos, M. de la Llera-Moya, G.E. Dallal, K.V. Horvath, E.J. Schaefer, and G.H. Rothblat Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux J Lipid Res 46 2005 2246 2253
73. R.S. Rosenson, H.B. Brewer Jr., and W.S. Davidson Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport Circulation 125 2012 1905 1919
74. B.F. Asztalos, D. Collins, and L.A. Cupples Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial Arterioscler Thromb Vasc Biol 25 2005 2185 2191
75. B.F. Asztalos, M. Batista, and K.V. Horvath Change in alpha1 HDL concentration predicts progression in coronary artery stenosis Arterioscler Thromb Vasc Biol 23 2003 847 852
76. J. Lounila, M. Ala-Korpela, J. Jokisaari, M.J. Savolainen, and Y.A. Kesaniemi Effects of orientational order and particle size on the NMR line positions of lipoproteins Phys Rev Lett 72 1994 4049 4052
77. J.D. Otvos Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy Clin Lab 48 2002 171 180
78. E.J. Jeyarajah, W.C. Cromwell, and J.D. Otvos Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy Clin Lab Med 26 2006 847 870
79. L.L. Rudel, C.A. Marzetta, and F.L. Johnson Separation and analysis of lipoproteins by gel filtration Methods Enzymol 129 1986 45 57
80. T. Sata, R.J. Havel, and A.L. Jones Characterization of subfractions of triglyceride-rich lipoproteins separated by gel chromatography from blood plasma of normolipemic and hyperlipemic humans J Lipid Res 13 1972 757 768
81. K. El Harchaoui, B.J. Arsenault, and R. Franssen High-density lipoprotein particle size and concentration and coronary risk Ann Intern Med 150 2009 84 93
82. S. Mora, J.D. Otvos, N. Rifai, R.S. Rosenson, J.E. Buring, and P.M. Ridker Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women Circulation 119 2009 931 939
83. M.P. Caulfield, S. Li, and G. Lee Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis Clin Chem 54 2008 1307 1316
84. K. Musunuru, M. Orho-Melander, and M.P. Caulfield Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk Arterioscler Thromb Vasc Biol 29 2009 1975 1980
85. P. Alaupovic The concept of apolipoprotein-defined lipoprotein families and its clinical significance Curr Atheroscler Rep 5 2003 459 467
86. R.W. James, D. Hochstrasser, and J.D. Tissot Protein heterogeneity of lipoprotein particles containing apolipoprotein A-I without apolipoprotein A-II and apolipoprotein A-I with apolipoprotein A-II isolated from human plasma J Lipid Res 29 1988 1557 1571
87. R.S. Rosenson, H.B. Brewer Jr., and M.J. Chapman HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events Clin Chem 57 2011 392 410
88. S.J. Nicholls, B. Cutri, and S.G. Worthley Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits Arterioscler Thromb Vasc Biol 25 2005 2416 2421
89. M. Sugano, N. Makino, and S. Sawada Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits J Biol Chem 273 1998 5033 5036
90. C.W. Rittershaus, D.P. Miller, and L.J. Thomas Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis Arterioscler Thromb Vasc Biol 20 2000 2106 2112
91. H. Okamoto, F. Yonemori, K. Wakitani, T. Minowa, K. Maeda, and H. Shinkai A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits Nature 406 2000 203 207
92. L.A. Morehouse, E.D. Sugarman, and P.A. Bourassa Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits J Lipid Res 48 2007 1263 1272
93. C.P. Cannon, B.A. Steinberg, S.A. Murphy, J.L. Mega, and E. Braunwald Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy J Am Coll Cardiol 48 2006 438 445
94. Cholesterol Treatment Trialists' (CTT) Collaboration C. Baigent, and L. Blackwell Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
95. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group J. Armitage, and L. Bowman Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial Lancet 376 2010 1658 1669
96. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
97. H.B. Rubins, S.J. Robins, and D. Collins Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group Am J Cardiol 75 1995 1196 1201
98. J. Genest Jr., J.R. McNamara, and J.M. Ordovas Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease J Am Coll Cardiol 19 1992 792 802
99. D.J. Rader Molecular regulation of HDL metabolism and function: implications for novel therapies J Clin Invest 116 2006 3090 3100
100. C.D. Meyers, and M.L. Kashyap Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies Curr Opin Cardiol 20 2005 307 312
101. G.M. Reaven Syndrome X: 6 years later J Intern Med Suppl 736 1994 13 22
102. V.L. Roger, A.S. Go, and D.M. Lloyd-Jones Heart disease and stroke statistics-2011 update: a report from the American Heart Association Circulation 123 2011 e18 e209
103. R.B. Ervin Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006 Natl Health Stat Rep 13 2009 1 7
104. D.M. Lloyd-Jones, E.P. Leip, and M.G. Larson Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age Circulation 113 2006 791 798
105. I.M. Singh, M.H. Shishehbor, and B.J. Ansell High-density lipoprotein as a therapeutic target: a systematic review JAMA 298 2007 786 798
106. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study Circulation 102 2000 21 27
107. A. Keech, R.J. Simes, and P. Barter Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
108. A.S. Group, H.N. Ginsberg, and M.B. Elam Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
109. R. Scott, R. O'Brien, and G. Fulcher Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study Diabetes Care 32 2009 493 498
110. F.M. Sacks, V.J. Carey, and J.C. Fruchart Combination lipid therapy in type 2 diabetes N Engl J Med 363 2010 692 694 [author reply 694-695]
111. Clofibrate and niacin in coronary heart disease JAMA 231 1975 360 381
112. P.L. Canner, K.G. Berge, and N.K. Wenger Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin J Am Coll Cardiol 8 1986 1245 1255
113. L.A. Carlson, and G. Rosenhamer Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid Acta Med Scand 223 1988 405 418
114. D.H. Blankenhorn, S.A. Nessim, R.L. Johnson, M.E. Sanmarco, S.P. Azen, and L. Cashin-Hemphill Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts JAMA 257 1987 3233 3240
115. L. Cashin-Hemphill, W.J. Mack, J.M. Pogoda, M.E. Sanmarco, S.P. Azen, and D.H. Blankenhorn Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up JAMA 264 1990 3013 3017
116. G. Brown, J.J. Albers, and L.D. Fisher Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B N Engl J Med 323 1990 1289 1298
117. B.G. Brown, A. Brockenbrough, and X.-Q. Zhao Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction: a 10-year familial atherosclerosis treatment study (FATS) follow-up [Abstract 3341] Circulation 98 suppl I 1998 I-635
118. B.G. Brown, X.Q. Zhao, and A. Chait Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592
119. A.J. Taylor, L.E. Sullenberger, H.J. Lee, J.K. Lee, and K.A. Grace Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins Circulation 110 2004 3512 3517
120. A.J. Taylor, H.J. Lee, and L.E. Sullenberger The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3 Curr Med Res Opin 22 2006 2243 2250
121. A.J. Taylor, T.C. Villines, and E.J. Stanek Extended-release niacin or ezetimibe and carotid intima-media thickness N Engl J Med 361 2009 2113 2122
122. T.C. Villines, E.J. Stanek, and P.J. Devine The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration J Am Coll Cardiol 55 2010 2721 2726
123. J.M. Lee, M.D. Robson, and L.M. Yu Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study J Am Coll Cardiol 54 2009 1787 1794
124. J.S. Morse, B.G. Brown, and X.Q. Zhao Niacin plus simvastatin protect against atherosclerosis progression and clinical events in CAD patients with low HDL-C and diabetes mellitus or impaired fasting glucose J Am Coll Cardiol 37 suppl A 2001 262A
125. P.L. Canner, C.D. Furberg, M.L. Terrin, and M.E. McGovern Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project) Am J Cardiol 95 2005 254 257
126. P.L. Canner, C.D. Furberg, and M.E. McGovern Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project) Am J Cardiol 97 2006 477 479
127. AIM-HIGH Investigators The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH) Am Heart J 161 2011 471 477 e2
128. HPS2-THRIVE Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 2013 1279 1291
129. W.L. Song, J. Stubbe, and E. Ricciotti Niacin and biosynthesis of PGD(2)by platelet COX-1 in mice and humans J Clin Invest 122 2012 1459 1468
130. U. Landmesser The difficult search for a 'partner' of statins in lipid-targeted prevention of vascular events: the re-emergence and fall of niacin Eur Heart J 34 2013 1254 1257
131. P.M. Lavigne, and R.H. Karas The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression J Am Coll Cardiol 61 2013 440 446
132. A. Thompson, E. Di Angelantonio, and N. Sarwar Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk JAMA 299 2008 2777 2788
133. P.M. Ridker, G. Pare, A.N. Parker, R.Y. Zee, J.P. Miletich, and D.I. Chasman Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18245 initially healthy women from the Women's Genome Health Study Circ Cardiovasc Genet 2 2009 26 33
134. L. Yvan-Charvet, F. Matsuura, and N. Wang Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL Arterioscler Thromb Vasc Biol 27 2007 1132 1138
135. S.J. Nicholls, E.M. Tuzcu, D.M. Brennan, J.C. Tardif, and S.E. Nissen Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation) Circulation 118 2008 2506 2514
136. P.J. Barter, and K.A. Rye Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk J Lipid Res 53 2012 1755 1766
137. R. Waksman, R. Torguson, and K.M. Kent A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome J Am Coll Cardiol 55 2010 2727 2735
138. C.P. Cannon, S. Shah, and H.M. Dansky Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
139. S.J. Nicholls, H.B. Brewer, and J.J. Kastelein Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial JAMA 306 2011 2099 2109
140. P.J. Barter, and K.A. Rye Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol 28 2008 39 46
141. M. Jun, C. Foote, and J. Lv Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis Lancet 375 2010 1875 1884
142. L.M. Younk, L. Uhl, and S.N. Davis Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk Expert Opin Drug Metab Toxicol 7 2011 753 763
143. D. Bailey, R. Jahagirdar, and A. Gordon RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo J Am Coll Cardiol 55 2010 2580 2589
144. S.J. Nicholls, A. Gordon, and J. Johansson Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial J Am Coll Cardiol 57 2011 1111 1119
145. S.J. Nicholls, A. Gordon, and J. Johannson ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies Cardiovasc Drugs Ther 26 2012 181 187
146. D.J. Rader, E.T. Alexander, G.L. Weibel, J. Billheimer, and G.H. Rothblat Role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis J Lipid Res 50 2009 S189 S194
147. Y. Zhang, I. Zanotti, M.P. Reilly, J.M. Glick, G.H. Rothblat, and D.J. Rader Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo Circulation 108 2003 661 663
148. L. Yvan-Charvet, N. Wang, and A.R. Tall Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses Arterioscler Thromb Vasc Biol 30 2010 139 143
149. A.E. van der Velde, G. Brufau, and A.K. Groen Transintestinal cholesterol efflux Curr Opin Lipidol 21 2010 167 171
150. J.A. Glomset The plasma lecithins:cholesterol acyltransferase reaction J Lipid Res 9 1968 155 167
151. G.H. Rothblat, and M.C. Phillips High-density lipoprotein heterogeneity and function in reverse cholesterol transport Curr Opin Lipidol 21 2010 229 238
152. R.E. Moore, M. Navab, and J.S. Millar Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation Circ Res 97 2005 763 771
153. Y. Zhang, J.R. Da Silva, M. Reilly, J.T. Billheimer, G.H. Rothblat, and D.J. Rader Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo J Clin Invest 115 2005 2870 2874
154. S.U. Naik, X. Wang, and J.S. Da Silva Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo Circulation 113 2006 90 97
155. K. Nakaya, J. Tohyama, and S.U. Naik Peroxisome proliferator-activated receptor-alpha activation promotes macrophage reverse cholesterol transport through a liver X receptor-dependent pathway Arterioscler Thromb Vasc Biol 31 2011 1276 1282
156. S. Yamamoto, H. Tanigawa, X. Li, Y. Komaru, J.T. Billheimer, and D.J. Rader Pharmacologic suppression of hepatic ATP-binding cassette transporter 1 activity in mice reduces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport Circulation 124 2011 1382 1390
157. M. de la Llera-Moya, D. Drazul-Schrader, B.F. Asztalos, M. Cuchel, D.J. Rader, and G.H. Rothblat The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages Arterioscler Thromb Vasc Biol 30 2010 796 801
158. A.V. Khera, M. Cuchel, and M. de la Llera-Moya Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N Engl J Med 364 2011 127 135
159. S. Larrede, C.M. Quinn, and W. Jessup Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent Arterioscler Thromb Vasc Biol 29 2009 1930 1936
160. M. Eriksson, L.A. Carlson, T.A. Miettinen, and B. Angelin Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I: potential reverse cholesterol transport in humans Circulation 100 1999 594 598
161. M.E. Brousseau, M.R. Diffenderfer, and J.S. Millar Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion Arterioscler Thromb Vasc Biol 25 2005 1057 1064
162. S. Turner, J. Voogt, and M. Davidson Measurement of reverse cholesterol transport pathways in humans: in vivo rates of free cholesterol efflux, esterification, and excretion J Am Heart Assoc 1 2012 e001826
163. A.G. Holleboom, R. Franssen, and L. Jakulj In vivo tissue cholesterol efflux is impaired in carriers of mutations in APOA1 and ABCA1 Circulation 122 2010 A17881
164. M. Cuchel, J.T. Billheimer, and J.S. Millar Assessment of reverse cholesterol transport in vivo in humans: a novel method Arterioscler Thromb Vasc Biol 32 2012 A71
165. A. Nilsson, and D.B. Zilversmit Fate of intravenously administered particulate and lipoprotein cholesterol in the rat J Lipid Res 13 1972 32 38
166. C.C. Schwartz, L.G. Halloran, Z.R. Vlahcevic, D.H. Gregory, and L. Swell Preferential utilization of free cholesterol from high-density lipoproteins for biliary cholesterol secretion in man Science 200 1978 62 64
167. C.C. Schwartz, M. Berman, Z.R. Vlahcevic, and L. Swell Multicompartmental analysis of cholesterol metabolism in man. Quantitative kinetic evaluation of precursor sources and turnover of high density lipoprotein cholesterol esters J Clin Invest 70 1982 863 876
168. C.C. Schwartz, L.A. Zech, J.M. Vandenbroek, and P.S. Cooper Cholesterol kinetics in subjects with bile fistula. Positive relationship between size of the bile acid precursor pool and bile acid synthetic rate J Clin Invest 91 1993 923 938
169. C.C. Schwartz, J.M. VandenBroek, and P.S. Cooper Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans J Lipid Res 45 2004 1594 1607
170. A. Kontush, and M.J. Chapman High-Density Lipoproteins: Structure, Metabolism, Function and Therapeutics 2012 Wiley & Sons New York, NY
171. M.P. Adorni, F. Zimetti, and J.T. Billheimer The roles of different pathways in the release of cholesterol from macrophages J Lipid Res 48 2007 2453 2462
172. X. Gu, B. Trigatti, S. Xu, S. Acton, J. Babitt, and M. Krieger The efficient cellular uptake of high density lipoprotein lipids via scavenger receptor class B type I requires not only receptor-mediated surface binding but also receptor-specific lipid transfer mediated by its extracellular domain J Biol Chem 273 1998 26338 26348
173. M. Navab, S.S. Imes, and S.Y. Hama Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein J Clin Invest 88 1991 2039 2046
174. P.J. Barter, and K.A. Rye High density lipoproteins and coronary heart disease Atherosclerosis 121 1996 1 12
175. M.I. Concha, V.J. Smith, K. Castro, A. Bastias, A. Romero, and R.J. Amthauer Apolipoproteins A-I and A-II are potentially important effectors of innate immunity in the teleost fish Cyprinus carpio Eur J Biochem 271 2004 2984 2990
176. F. Villarroel, A. Bastias, A. Casado, R. Amthauer, and M.I. Concha Apolipoprotein A-I, an antimicrobial protein in Oncorhynchus mykiss: evaluation of its expression in primary defence barriers and plasma levels in sick and healthy fish Fish Shellfish Immunol 23 2007 197 209
177. L.D. Johnston, G. Brown, D. Gauthier, K. Reece, H. Kator, and P. Van Veld Apolipoprotein A-I from striped bass (Morone saxatilis) demonstrates antibacterial activity in vitro Comp Biochem Physiol B Biochem Mol Biol 151 2008 167 175
178. P.M. Figueiredo, C.F. Catani, and T. Yano Serum high-density lipoprotein (HDL) inhibits in vitro enterohemolysin (EHly) activity produced by enteropathogenic Escherichia coli FEMS Immunol Med Microbiol 38 2003 53 57
179. C. Grunfeld, M. Marshall, J.K. Shigenaga, A.H. Moser, P. Tobias, and K.R. Feingold Lipoproteins inhibit macrophage activation by lipoteichoic acid J Lipid Res 40 1999 245 252
180. J. Ma, X.L. Liao, B. Lou, and M.P. Wu Role of apolipoprotein A-I in protecting against endotoxin toxicity Acta Biochim Biophys Sin (Shanghai) 36 2004 419 424
181. T.S. Parker, D.M. Levine, J.C. Chang, J. Laxer, C.C. Coffin, and A.L. Rubin Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood Infect Immun 63 1995 253 258
182. Y.L. Jiao, and M.P. Wu Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid Cytokine 43 2008 83 87
183. Y. Li, J.B. Dong, and M.P. Wu Human ApoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice Eur J Pharmacol 590 2008 417 422
184. J.R. Nofer, M.F. Brodde, and B.E. Kehrel High-density lipoproteins, platelets and the pathogenesis of atherosclerosis Clin Exp Pharmacol Physiol 37 2010 726 735
185. A. Jahangiri High-density lipoprotein and the acute phase response Curr Opin Endocrinol Diabetes Obes 17 2010 156 160
186. S.M. Gordon, S. Hofmann, D.S. Askew, and W.S. Davidson High density lipoprotein: it's not just about lipid transport anymore Trends Endocrinol Metab 22 2011 9 15
187. H. Karlsson, P. Leanderson, C. Tagesson, and M. Lindahl Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry Proteomics 5 2005 1431 1445
188. M. Heller, D. Stalder, E. Schlappritzi, G. Hayn, U. Matter, and A. Haeberli Mass spectrometry-based analytical tools for the molecular protein characterization of human plasma lipoproteins Proteomics 5 2005 2619 2630
189. G.L. Hortin, R.F. Shen, B.M. Martin, and A.T. Remaley Diverse range of small peptides associated with high-density lipoprotein Biochem Biophys Res Commun 340 2006 909 915
190. F. Rezaee, B. Casetta, J.H. Levels, D. Speijer, and J.C. Meijers Proteomic analysis of high-density lipoprotein Proteomics 6 2006 721 730
191. T. Vaisar, S. Pennathur, and P.S. Green Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL J Clin Invest 117 2007 746 756
192. W.S. Davidson, R.A. Silva, S. Chantepie, W.R. Lagor, M.J. Chapman, and A. Kontush Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function Arterioscler Thromb Vasc Biol 29 2009 870 876
193. K. Alwaili, D. Bailey, and Z. Awan The HDL proteome in acute coronary syndromes shifts to an inflammatory profile Biochim Biophys Acta 1821 2012 405 415
194. M. Holzer, P. Wolf, and S. Curcic Psoriasis alters HDL composition and cholesterol efflux capacity J Lipid Res 53 2012 1618 1624
195. M. Holzer, R. Birner-Gruenberger, and T. Stojakovic Uremia alters HDL composition and function J Am Soc Nephrol 22 2011 1631 1641
196. T. Weichhart, C. Kopecky, and M. Kubicek Serum amyloid A in uremic HDL promotes inflammation J Am Soc Nephrol 23 2012 934 947
197. A. Mange, A. Goux, and S. Badiou HDL proteome in hemodialysis patients: a quantitative nanoflow liquid chromatography-tandem mass spectrometry approach PloS One 7 2012 e34107
198. J. Watanabe, C. Charles-Schoeman, and Y. Miao Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis Arthritis Rheum 64 2012 1828 1837
199. S.M. Gordon, J. Deng, L.J. Lu, and W.S. Davidson Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography J Proteome Res 9 2010 5239 5249
200. A.S. Shah, L. Tan, J. Lu Long, and W.S. Davidson The proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond J Lipid Res. 54 2013 2575 2585
201. R.D. Santos, E.J. Schaefer, and B.F. Asztalos Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency J Lipid Res 49 2008 349 357
202. M.R. Rifkin Identification of the trypanocidal factor in normal human serum: high density lipoprotein Proc Natl Acad Sci U S A 75 1978 3450 3454
203. M.K. Jensen, E.B. Rimm, J.D. Furtado, and F.M. Sacks Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease J Am Heart Assoc 1 2012
204. H. Karlsson, P. Leanderson, C. Tagesson, and M. Lindahl Lipoproteomics I: mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry Proteomics 5 2005 551 565
205. H. Karlsson, H. Mortstedt, H. Lindqvist, C. Tagesson, and M. Lindahl Protein profiling of low-density lipoprotein from obese subjects Proteomics Clin Appl 3 2009 663 671
206. M. Stahlman, P. Davidsson, and I. Kanmert Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr J Lipid Res 49 2008 481 490
207. C. Mancone, L. Amicone, and G.M. Fimia Proteomic analysis of human very low-density lipoprotein by two-dimensional gel electrophoresis and MALDI-TOF/TOF Proteomics 7 2007 143 154
208. T. Vaisar, P. Mayer, E. Nilsson, X.Q. Zhao, R. Knopp, and B.J. Prazen HDL in humans with cardiovascular disease exhibits a proteomic signature Clin Chim Acta 411 2010 972 979
209. P.S. Green, T. Vaisar, and S. Pennathur Combined statin and niacin therapy remodels the high-density lipoprotein proteome Circulation 118 2008 1259 1267
210. K.B. Rubinow, C. Tang, and A.N. Hoofnagle Acute sex steroid withdrawal increases cholesterol efflux capacity and HDL-associated clusterin in men Steroids 77 2012 454 460
211. K.B. Rubinow, T. Vaisar, C. Tang, A.M. Matsumoto, J.W. Heinecke, and S.T. Page Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity J Lipid Res 53 2012 1376 1383
212. P. Wiesner, K. Leidl, A. Boettcher, G. Schmitz, and G. Liebisch Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry J Lipid Res 50 2009 574 585
213. L. Yetukuri, S. Soderlund, and A. Koivuniemi Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol J Lipid Res 51 2010 2341 2351
214. O. Quehenberger, A.M. Armando, and A.H. Brown Lipidomics reveals a remarkable diversity of lipids in human plasma J Lipid Res 51 2010 3299 3305
215. A. Kontush, P. Therond, and A. Zerrad Preferential sphingosine-1- phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities Arterioscler Thromb Vasc Biol 27 2007 1843 1849
216. M. Scherer, A. Bottcher, G. Schmitz, and G. Liebisch Sphingolipid profiling of human plasma and FPLC-separated lipoprotein fractions by hydrophilic interaction chromatography tandem mass spectrometry Biochim Biophys Acta 1811 2011 68 75
217. J.Y. Lee, H.K. Min, D. Choi, and M.H. Moon Profiling of phospholipids in lipoproteins by multiplexed hollow fiber flow field-flow fractionation and nanoflow liquid chromatography-tandem mass spectrometry J Chromatogr A 1217 2010 1660 1666
218. H. Deguchi, J.A. Fernandez, T.M. Hackeng, C.L. Banka, and J.H. Griffin Cardiolipin is a normal component of human plasma lipoproteins Proc Natl Acad Sci U S A 97 2000 1743 1748
219. W.S. Davidson, D.L. Sparks, S. Lund-Katz, and M.C. Phillips The molecular basis for the difference in charge between pre-beta- and alpha-migrating high density lipoproteins J Biol Chem 269 1994 8959 8965
220. J.G. Boucher, T. Nguyen, and D.L. Sparks Lipoprotein electrostatic properties regulate hepatic lipase association and activity Biochem Cell Biol 85 2007 696 708
221. V.W. Bowry, K.K. Stanley, and R. Stocker High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors Proc Natl Acad Sci U S A 89 1992 10316 10320
222. B. Garner, P.K. Witting, A.R. Waldeck, J.K. Christison, M. Raftery, and R. Stocker Oxidation of high density lipoproteins, I: formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol J Biol Chem 273 1998 6080 6087
223. S. Goulinet, and M.J. Chapman Plasma LDL and HDL subspecies are heterogenous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenesis Arterioscler Thromb Vasc Biol 17 1997 786 796
224. V.P. Skipski, M. Barclay, R.K. Barclay, V.A. Fetzer, J.J. Good, and F.M. Archibald Lipid composition of human serum lipoproteins Biochem J 104 1967 340 352
225. G. Dawson, A.W. Kruski, and A.M. Scanu Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias J Lipid Res 17 1976 125 131
226. H.J. Senn, M. Orth, E. Fitzke, H. Wieland, and W. Gerok Gangliosides in normal human serum. Concentration, pattern and transport by lipoproteins Eur J Biochem 181 1989 657 662
227. F. Lalanne, V. Pruneta, S. Bernard, and G. Ponsin Distribution of diacylglycerols among plasma lipoproteins in control subjects and in patients with non-insulin-dependent diabetes Eur J Clin Invest 29 1999 139 144
228. J.R. Nofer, and G. Assmann Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids Trends Cardiovasc Med 15 2005 265 271
229. A. Nilsson, and R.D. Duan Absorption and lipoprotein transport of sphingomyelin J Lipid Res 47 2006 154 171
230. A. Kontush, S. Chantepie, and M.J. Chapman Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress Arterioscler Thromb Vasc Biol 23 2003 1881 1888
231. Y. Nakamura, L. Kotite, Y. Gan, T.A. Spencer, C.J. Fielding, and P.E. Fielding Molecular mechanism of reverse cholesterol transport: reaction of pre-beta-migrating high-density lipoprotein with plasma lecithin/cholesterol acyltransferase Biochemistry 43 2004 14811 14820
232. J.A. de Souza, C. Vindis, and A. Negre-Salvayre Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I J Cell Mol Med 14 2010 608 620
233. J.A. de Souza, C. Vindis, and B. Hansel Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity Atherosclerosis 197 2008 84 94
234. C. Christoffersen, H. Obinata, and S.B. Kumaraswamy Endothelium- protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M Proc Natl Acad Sci U S A 108 2011 9613 9618
235. P.G. Yancey, M. de la Llera-Moya, and S. Swarnakar High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI J Biol Chem 275 2000 36596 36604
236. W.S. Davidson, K.L. Gillotte, S. Lund-Katz, W.J. Johnson, G.H. Rothblat, and M.C. Phillips The effect of high density lipoprotein phospholipid acyl chain composition on the efflux of cellular free cholesterol J Biol Chem 270 1995 5882 5890
237. B.J. Litman, E.N. Lewis, and I.W. Levin Packing characteristics of highly unsaturated bilayer lipids: Raman spectroscopic studies of multilamellar phosphatidylcholine dispersions Biochemistry 30 1991 313 319
238. A. Zerrad-Saadi, P. Therond, and S. Chantepie HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis Arterioscler Thromb Vasc Biol 29 2009 2169 2175
239. M. Tolle, A. Pawlak, and M. Schuchardt HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production Arterioscler Thromb Vasc Biol 28 2008 1542 1548
240. Y.G. Kwon, J.K. Min, K.M. Kim, D.J. Lee, T.R. Billiar, and Y.M. Kim Sphingosine 1-phosphate protects human umbilical vein endothelial cells from serum-deprived apoptosis by nitric oxide production J Biol Chem 276 2001 10627 10633
241. C. Mineo, H. Deguchi, J.H. Griffin, and P.W. Shaul Endothelial and antithrombotic actions of HDL Circ Res 98 2006 1352 1364
242. J.R. Nofer, M. van der Giet, and M. Tolle HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3 J Clin Invest 113 2004 569 581
243. J. Igarashi, and T. Michel S1P and eNOS regulation Biochim Biophys Acta 1781 2008 489 495
244. Y. Matsuo, S. Miura, A. Kawamura, Y. Uehara, K.A. Rye, and K. Saku Newly developed reconstituted high-density lipoprotein containing sphingosine-1- phosphate induces endothelial tube formation Atherosclerosis 194 2007 159 168
245. C. Mineo, and P.W. Shaul Novel biological functions of high-density lipoprotein cholesterol Circ Res 111 2012 1079 1090
246. K.C. Vickers, B.T. Palmisano, B.M. Shoucri, R.D. Shamburek, and A.T. Remaley MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins Nat Cell Biol 13 2011 423 433
247. A. Kontush, and M.J. Chapman Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis Pharmacol Rev 58 2006 342 374
248. R.M. Krauss, K. Wojnooski, and J. Orr Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib J Lipid Res 53 2012 540 547
249. J. Castro-Perez, F. Briand, and K. Gagen Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters J Lipid Res 52 2011 1965 1973
250. D.J. Gordon, and B.M. Rifkind High-density lipoprotein-the clinical implications of recent studies N Engl J Med 321 1989 1311 1316
251. P.W. Wilson, R.D. Abbott, and W.P. Castelli High density lipoprotein cholesterol and mortality. The Framingham Heart Study Arteriosclerosis 8 1988 737 741
252. A.R. Tall, P. Costet, and N. Wang Regulation and mechanisms of macrophage cholesterol efflux J Clin Invest 110 2002 899 904
253. R. Frikke-Schmidt, B.G. Nordestgaard, and M.C. Stene Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease JAMA 299 2008 2524 2532
254. S.D. Covey, M. Krieger, W. Wang, M. Penman, and B.L. Trigatti Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells Arterioscler Thromb Vasc Biol 23 2003 1589 1594
255. P.J. Barter, S. Nicholls, K.A. Rye, G.M. Anantharamaiah, M. Navab, and A.M. Fogelman Antiinflammatory properties of HDL Circ Res 95 2004 764 772
256. L.E. Spieker, I. Sudano, and D. Hurlimann High-density lipoprotein restores endothelial function in hypercholesterolemic men Circulation 105 2002 1399 1402
257. M. Zabalawi, M. Bharadwaj, and H. Horton Inflammation and skin cholesterol in LDLr-/-, apoA-I-/- mice: link between cholesterol homeostasis and self-tolerance? J Lipid Res 48 2007 52 65
258. M. Navab, G.M. Anantharamaiah, and S.T. Reddy The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL J Lipid Res 45 2004 993 1007
259. R. Ross Atherosclerosis-an inflammatory disease N Engl J Med 340 1999 115 126
260. J. Danesh, P. Whincup, and M. Walker Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses BMJ 321 2000 199 204
261. P.M. Ridker, N. Rifai, and M.A. Pfeffer Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators Circulation 98 1998 839 844
262. B.J. Van Lenten, S.Y. Hama, and F.C. de Beer Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures J Clin Invest 96 1995 2758 2767
263. A.M. Berard, B. Foger, and A. Remaley High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase Nat Med 3 1997 744 749
264. B. Shao, M.N. Oda, J.F. Oram, and J.W. Heinecke Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein Chem Res Toxicol 23 2010 447 454
265. C.L. Banka, T. Yuan, M.C. de Beer, M. Kindy, L.K. Curtiss, and F.C. de Beer Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux J Lipid Res 36 1995 1058 1065
266. J.D. Otvos The surprising AIM-HIGH results are not surprising when viewed through a particle lens J Clin Lipidol 5 2011 368 370
267. R.H. Mackey, P. Greenland, D.C. Goff Jr., D. Lloyd-Jones, C.T. Sibley, and S. Mora High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multi-Ethnic Study of Atherosclerosis) J Am Coll Cardiol 60 2012 508 516
268. W.B. Kannel, and P.W.F. Wilson Efficacy of lipid profiles in prediction of coronary disease Am Heart J 124 1992 768 774